We recently published a list of the 15 Best Dividend Aristocrat Stocks with Over 3% Yield. In this article, we are going to ...
AbbVie has filed a lawsuit against Genmab, accusing the Danish drugmaker of being “intentionally and willfully blind” to the ...
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...
Zacks Investment Research on MSN3d
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should KnowAbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...
Imagine standing on a vast, dark plain. Without light, you cannot see dips and rolls in the grass or make out hills and ...
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...
As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...
Investing in stocks comes with risks. There's no way around that fact. However, some stocks can be less risky than others during certain market conditions. Three Motley Fool contr ...
Zacks.com on MSN6d
AbbVie (ABBV) Stock Sinks As Market Gains: Here's WhyThe latest trading day saw AbbVie (ABBV) settling at $209.17, representing a -0.4% change from its previous close.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback